DE-THE-LYCRA-COMPANY
1.4.2021 22:04:04 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative solutions for the textile, apparel, and personal care industries, announces the appointment of Yafu Qiu, chairman of The LYCRA Company, and Julien Born, chief commercial officer of The LYCRA Company, as co-chief executive officers, effective April 1, 2021, following the retirement of David Trerotola. The co-ceo structure is intended to better implement The LYCRA Company’s new strategic development plan for the next five years and will bring greater operational focus and tap into each leader’s experience and skills in the areas most beneficial to the company to solidify its industry-leading position and drive its long-term success.
Mr. Trerotola served as the company’s chief executive officer since 2019, following the Ruyi Group’s acquisition of the business. Mr. Trerotola retires after 20 years of dedicated service to The LYCRA Company and its predecessor companies. He began his career in 1994 with DuPont.
“I want to thank Dave for his many contributions to The LYCRA Company,” said Yafu Qiu, chairman of The LYCRA Company, the company’s controlling shareholder. “Dave’s passion for the business was evident to me from the beginning, and I wish him all the best in this next phase of his journey with his wife and family. At my request, Dave will support a smooth transition of leadership and will be working with me and Julien over the next 60 days.”
Mr. Born, currently the company’s chief commercial officer, will serve as co-ceo and lead the overall operations of the company and implement its ambitious growth vision. Mr. Born joined the business in 2007 and, since 2018, led the company’s apparel business, where he managed the global commercial organization, helped strengthen R&D and innovation capabilities, and oversaw manufacturing assets. Mr. Born has also spent significant time in Asia, where he led that region over an eight-year period, with assignments in Shanghai and Hong Kong. Mr. Born has had a diverse 24-year career spent in the US, Europe and Asia, as both an executive in large multinational companies and as a business owner of a full-service corporate licensing agency. A native of Switzerland, Mr. Born holds a bachelor’s degree from Arizona State University’s W.P. Carey School of Business and a Swiss baccalaureate degree.
“The board has appointed Julien as The LYCRA Company’s next ceo,” said Mr. Qiu. “I am confident that Julien understands the opportunities and challenges facing the business and we are fully committed to supporting him and the entire leadership team on the new developments and performance growth of The LYCRA Company to help The LYCRA Company realize its full potential in 2021 and beyond.”
“I am excited for the opportunity to lead a tremendous team of colleagues at The LYCRA Company who are focused every day on creating value in the industries we serve via our unique brand portfolio, high-quality products, unparalleled innovation capabilities, and our global network of partners,” said Mr. Born. “I look forward to a close partnership with Chairman Qiu and the Ruyi Group to further develop our manufacturing capacity and accelerate the growth of our business, especially in China.”
Mr. Qiu, in addition to continuing as chairman of The LYCRA Company, will focus his co-ceo role on the company’s relationships with key stakeholders, board governance matters, strategic planning, and capital structure adjustments, including the strategy and timing of an initial public offering.
“The LYCRA Company is faced with many new challenges in a fast-developing world,” concluded Mr. Qiu. “We are taking this opportunity to appoint Mr. Born and other new management team members to work on a new strategy to further build our brand franchises, expand manufacturing capacity, develop more impactful innovations with our global value-chain partners, lead the industry in sustainability, and accelerate our digital transformation. I am confident that the new management team will be able to further strengthen the leadership role of The LYCRA Company in the apparel and personal care industries.”
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005877/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
